| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6827802 | Schizophrenia Research | 2011 | 7 Pages |
Abstract
These data suggest that interview-based cognitive measures such as the SCoRS may be sensitive to changes after 3Â weeks of treatment in patients with schizophrenia. Lurasidone is being assessed further in ongoing clinical trials with additional outcome measures.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Philip D. Harvey, Masaaki Ogasa, Josephine Cucchiaro, Antony Loebel, Richard S.E. Keefe,